Join Clinical Trials in Utah for Depression

All Categories Most Often Searched » Depression » Utah

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Condition: Major Depressive Disorder
Intervention: Drug: Creatine monohydrate or placebo
Sponsors: University of Utah; University of Utah
Not yet recruiting - verified May 2012
Efficacy of LuAA21004 on Cognitive Dysfunction in Major Depressive Disorder

Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: Duloxetine; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
Open-Label Creatine Monohydrate Supplementation in Depressed Female Methamphetamine Users

Conditions: Depression; Substance Abuse; Substance Use
Intervention: Drug: Creatine monohydrate
Sponsors: University of Utah; Perry Renshaw
Recruiting - verified April 2012
Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression

Condition: Major Depressive Disorder
Intervention:
Sponsors: University of Utah; Paul Carlson; Western Institute for Biomedical Research; Brain Institute, University of Utah; University of Utah; Molecular Imaging Program, Huntsman Cancer Institute
Recruiting - verified November 2011
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained-release 50 mg/day; Drug: desvenlafaxine succinate sustained-release 100 mg/day; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: tasimelteon; Drug: placebo
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2012
Major Depressive Disorder With Mixed Features - Extension

Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012
Major Depressive Disorder With Mixed Features

Condition: Major Depressive Disorder
Interventions: Drug: Lurasidone 20 mg; Drug: Lurasidone 60 mg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Not yet recruiting - verified November 2011
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

Condition: Depression
Interventions: Drug: Duloxetine; Drug: Escitalopram; Drug: BMS-820836 Placebo; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Condition: Depression
Interventions: Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified July 2011
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT; Drug: Placebo + ADT
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified July 2011
A Study in Prevention of Re-emergence of Depression Symptoms

Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Condition: Depression
Interventions: Drug: Duloxetine; Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: Duloxetine; Drug: Placebo matching with Duloxetine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

Condition: Treatment Resistant Depression
Interventions: Drug: CX157; Drug: Placebo
Sponsors: CeNeRx BioPharma Inc.; CeNeRx BioPharma Inc.
Recruiting - verified October 2011
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Condition: Major Depressive Disorder
Intervention: Drug: Escitalopram
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012
CSP #556 - The Effectiveness of rTMS in Depressed VA Patients

Condition: Major Depressive Disorder
Interventions: Device: rTMS; Device: Sham Device
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
Creatine Augmentation in Veterans With Selective Serotonin Reuptake Inhibitor (SSRI)-Resistant Major Depression

Condition: Major Depressive Disorder
Intervention: Drug: Creatine
Sponsors: University of Utah; University of Utah
Recruiting - verified October 2011
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram

Condition: Major Depressive Disorder
Intervention: Drug: Creatine Monohydrate
Sponsors: University of Utah; University of Utah; AlzChem, LLC
Recruiting - verified April 2012
Oral Uridine for Treatment of Bipolar Depression in Adolescents

Condition: Bipolar Disorder
Intervention: Drug: Oral Uridine
Sponsors: University of Utah; University of Utah; National Institute of Mental Health (NIMH)
Recruiting - verified April 2012
Late Hypothermia for Hypoxic-Ischemic Encephalopathy

Conditions: Infant, Newborn; Hypoxia, Brain; Hypoxia-Ischemia, Brain; Encephalopathy, Hypoxic-Ischemic; Hypoxic-Ischemic Encephalopathy; Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia; Procedure: Normothermic Control
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified September 2011